06 May WisBusiness: Cellectar Biosciences is reporting new positive results from its ongoing clinical trials for the company’s cancer therapy
In a Phase 2 clinical study of Cellectar’s lead drug candidate on patients with blood plasma cell cancer, researchers recorded a 30 percent response rate in the first 10 patients of the cohort.
The company had previously reported a 33 percent response rate in a separate group of patients who had lymphoma, a cancer of the body’s infection-fighting system.
According to James Caruso, president and CEO of the Madison-based company, Cellectar’s cancer therapy has been shown to affect at least three blood-related cancers.
“We continue to make significant progress in the clinic and are excited to now provide this promising treatment to pediatric cancer patients,” he said.
Along with the latest clinical results, the company released financial highlights for the first quarter of this year, showing research and development costs have risen slightly from the same period last year.
Read the full Cellectar Biosciences article here.